NCRM-1, NL-1
CRMi003-A
General#
Cell Line |
|
| hPSCreg Name | CRMi003-A |
| Alternative name(s) |
NCRM-1, NL-1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 12th September 2018 |
| User feedback | |
Provider |
|
| Generator | National Institutes of Health - Center for Regenerative Medicine (CRM) |
| Owner | National Institutes of Health - Regenerative Medicine Program |
| Distributors | |
| Derivation country | United States |
External Databases |
|
| BioSamples | SAMEA7777168 |
| Cellosaurus | CVCL_1E71 |
General Information |
|
| Projects | |
| Is the cell line available in principle? | Available with restrictions: Available for commercial research |
Donor Information#
General Donor Information |
|
| Sex | male |
| Ethnicity | unknown |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | unknown |
| Is the medical history available upon request? | no |
| Is clinical information available? | no |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46, XY
Karyotyping method:
G-Banding
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA7776418 |
Ethics#
We are currently revising this section.hIPSC Derivation#
General |
|
| Source cell type |
hematopoietic stem cellA stem cell from which all cells of the lymphoid and myeloid lineages develop, including blood cells and cells of the immune system. Hematopoietic stem cells lack cell markers of effector cells (lin-negative). Lin-negative is defined by lacking one or more of the following cell surface markers: CD2, CD3 epsilon, CD4, CD5 ,CD8 alpha chain, CD11b, CD14, CD19, CD20, CD56, ly6G, ter119.
Synonyms
|
| Source cell origin |
umbilical cord bloodblood that remains in the placenta and in the attached umbilical cord after childbirth[WP].
|
| Source cell type (free text) | Cord Blood CD34+ cells |
| Age of donor (at collection) | fetal |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Unkown |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Colony morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzymatically
Dispase
|
| O2 Concentration | 4 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
Differentiation Potency
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
33
|
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46 X,Y
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.